Stock listing

BMV:BIIB Biogen Inc. Acciones

Mexican listing (BMV) of Biogen Inc. · home listing NASDAQ:BIIB

Follow Biogen Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:BIIB

$233.48 USD +0.83 (+0.4%)

Close on Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:BIIB

Since Jul 6, 2026 +12.0% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$231.04 – $236.00 USDOct 19, 2026
Volume
949,473 sharesOct 19, 2026
Market value
$34.50B USDAt the close on Oct 19, 2026 · price × 147.8M shares outstanding
Biogen Inc. logo
Ticker
BMV:BIIB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BMV
Currency
MXN

What changed lately

Calls

Upcoming

  • Biogen (NASDAQ:BIIB) Q3 2026 Earnings Call

    Wed, Oct 28, 2026 · 8:30 AM ET

    Register

Replays

  • Biogen (NASDAQ:BIIB) Q2 2026 Earnings Call

    Wed, Jul 29, 2026 · 8:30 AM ET

    Watch Transcript

  • Biogen (NASDAQ:BIIB) Q1 2026 Earnings Call

    Wed, Apr 29, 2026 · 8:00 AM ET

    Watch Transcript

  • Biogen (NASDAQ:BIIB) Q4 2025 Earnings Call

    Fri, Feb 06, 2026 · 8:30 AM ET

    Watch Transcript

Latest news

Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week

Oct 19, 2026

Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

Oct 2, 2026

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

Sep 17, 2026

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease

Sep 16, 2026

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China

Sep 3, 2026

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease

Aug 31, 2026

Veeva Vault CRM Selected by Biogen

Aug 25, 2026

Issued by another party

LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease

Aug 24, 2026

Biogen Completes Acquisition of RayThera Inc.

Aug 6, 2026

Biogen Reports Second Quarter 2026 Results

Jul 29, 2026

All Biogen Inc. news

Decks

Biogen Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
79 in the last 12 months · 240 in all · newest Oct 19, 2026 · oldest 2021
Calls
26 calls with a replay · 26 with a transcript · latest Jul 29, 2026
Decks
49 decks · latest Jul 29, 2026

Where Biogen Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:BIIB · Home listingNASDAQUnited StatesUSD
gettex:IDPgettexGermanyEUR
BCBA:BIIBBCBAArgentinaARS
Tradegate:IDPTradegateGermanyEUR
LS Exchange:789617LS ExchangeGermanyEUR
BMV:BIIB · This pageBMVMexicoMXN
BCBA:BIIBDBCBAArgentinaUSD
Lang & Schwarz:789617Lang & SchwarzGermanyEUR
BCS:BIIBBCSChileUSD
LSE:0R1BLSEUnited KingdomUSD
Frankfurt:IDPFrankfurtGermanyEUR
Milan:1BIIBMilanItalyEUR
B3:BIIB34B3BrazilBRL
BOATS:BIIBBOATSUnited StatesUSD
Stuttgart:IDPStuttgartGermanyEUR
BIVA:BIIBBIVAMexicoMXN
Hamburg:IDPHamburgGermanyEUR
SIX Swiss:BIIB.USDSIX SwissSwitzerlandUSD
Munich:IDPMunichGermanyEUR
VIE:BIIBViennaAustriaEUR
Dusseldorf:IDPDusseldorfGermanyEUR
Hanover:IDPHanoverGermanyEUR
SIX Swiss:BIIBSIX SwissSwitzerlandCHF
BCS:BIIBCLBCSChileCLP
Turquoise:BIIBNTurquoiseUnited KingdomUSD
BCBA:BIIBCBCBAArgentinaUSD
EUROTLX:4BIIBEUROTLXItalyEUR
BX Swiss:IDPBX SwissSwitzerlandCHF
BCBA:BIIB.CIBCBAArgentinaARS
Xetra:IDPXetraGermanyEUR

Log in to ask 6ix AI your own questions about Biogen Inc.